Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,501 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01307631 | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03101046 | Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic(TACTIK) | completed | Phase 2 | 40 | UNICANCEROTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT00096200 | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00886691 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 150 | GOG FoundationNETWORK | 1 | Feb 4, 2022 | clinicaltrials |
| NCT02601014 | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7(STARVE-PC) | completed | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT00112840 | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01399918 | Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT02673151 | 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment | completed | Phase 2 / Phase 3 | 61 | Andrei IagaruOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT02849990 | A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT01566747 | Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | completed | Phase 2 | 43 | Cancer Trials IrelandNETWORK | 2 | Dec 23, 2021 | clinicaltrials |
| NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | completed | Phase 1 / Phase 2 | 28 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT03430895 | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | completed | Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT02711956 | A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Zenith EpigeneticsINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
| NCT00550277 | LBH589 Treatment for Refractory Clear Cell Renal Carcinoma | completed | Phase 2 | 20 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT02280317 | Dose Finding Safety Study of VAL201 in Cancer Patients(VAL201-001) | completed | Phase 1 / Phase 2 | 12 | ValiRx PlcINDUSTRY | 0 | Nov 8, 2021 | clinicaltrials |
| NCT02657928 | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01720173 | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 30 | Gynecologic Oncology GroupNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01853644 | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer(TIVO) | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03013335 | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen(NIVOREN) | completed | Phase 2 | 730 | UNICANCEROTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT04050215 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | completed | Phase 2 | 937 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT03339219 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | completed | Phase 2 | 35 | TakedaINDUSTRY | 1 | Sep 20, 2021 | clinicaltrials |
| NCT02346578 | Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | completed | Phase 2 | 104 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03685695 | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT02599779 | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients(OZM-065) | completed | Phase 2 | 4 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01896271 | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | completed | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT01024920 | Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 5 | Jul 19, 2021 | clinicaltrials |
| NCT02989714 | Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer | completed | Phase 1 / Phase 2 | 13 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT03494816 | Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion(NAXIVA) | completed | Phase 2 | 24 | Scottish Clinical Trials Research UnitOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT00118040 | Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02009332 | Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | Aadi Bioscience, Inc.INDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT02118337 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 97 | MedImmune LLCINDUSTRY | 6 | Jun 1, 2021 | clinicaltrials |
| NCT01503229 | Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT01540071 | Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | completed | Phase 2 | 38 | Io TherapeuticsINDUSTRY | 1 | May 14, 2021 | clinicaltrials |
| NCT03354884 | caBozantinib in cOllectiNg ductS Renal Cell cArcInoma(BONSAI) | completed | Phase 2 | 23 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT03463681 | A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma(BREAKPOINT) | completed | Phase 2 | 49 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT02987829 | Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 72 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 23, 2021 | clinicaltrials |
| NCT02127710 | A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) | completed | Phase 2 | 111 | AstraZenecaINDUSTRY | 4 | Apr 19, 2021 | clinicaltrials |
| NCT00121251 | Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT01468532 | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 18 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT02363751 | Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)(BEVABEL) | completed | Phase 2 | 36 | UNICANCEROTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00827359 | Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT01835158 | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | completed | Phase 2 | 157 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2021 | clinicaltrials |
| NCT01146795 | Neoadjuvant Therapy for Ovarian Cancer | completed | Phase 2 | 32 | Jason D. WrightOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Feb 11, 2022source: clinicaltrials